Navigation Links
NuVasive to Host Investor Reception on September 11, 2007
Date:9/7/2007

Waldorf=Astoria Hotel New York City 5:30-7:30 p.m. (ET)

SAN DIEGO, Sept. 7 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that it will host an investor reception for institutional investors and analysts at the Waldorf=Astoria Hotel in New York City on Tuesday, September 11, 2007, from 5:30 p.m. to 7:30 p.m. ET.

The reception will be hosted by NuVasive and includes presentations by senior management and top academic and private leading physicians from New York, Washington, DC and Texas. The physicians will participate in an interactive surgeon panel presentation covering key clinical updates, including an update from a surgeon participating in the NeoDisc clinical trial, as well as physician experience with XLIF(R) and new products launched during the first half of 2007 (SpheRx(R) II, XLP(TM) Lateral Plate and Formagraft(R)). Senior management and guest physicians will also participate in a question and answer session.

NuVasive senior management at the reception will include:

* Alex Lukianov, Chairman and Chief Executive Officer

* Keith Valentine, President and Chief Operating Officer

* Kevin O'Boyle, Executive Vice President and Chief Financial Officer

* Pat Miles, Executive Vice President of Marketing and Development

* Jeff Rydin, Senior Vice President, U.S. Sales

* Jason Hannon, Senior Vice President and General Counsel

Participants in the physician panel will include:

* Andrew Cappuccino, MD, Director Buffalo Spine Surgery and Assistant

Clinical Professor at SUNY, Buffalo, NY

* Randall Dryer, MD, Attending Orthopedic Surgeon, Central Texas Spine

Institute, Austin, TX

* Eric Elowitz, MD, Attending Neurosurgeon at St. Luke's-Roosevelt and

Beth Israel Hospitals and Assistant Professor of Neurological Surgery

at Albert Einstein College of Medicine, New York, NY

* Faheem Sandhu, MD, Assistant Professor, Department of Neurosurgery and

Director of Complex and Minimally Invasive Spinal Surgery at Georgetown

University Hospital, Washington, DC.

A live Web cast of the investor reception presentations will be available online from the investor relations page of the Company's corporate Web site at http://www.nuvasive.com. After the live Web cast, the presentation will remain available on NuVasive's Web site, http://www.nuvasive.com, for 30 days.

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $3.6 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(TM), as well as a growing offering of cervical and motion preservation products.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision(R) a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's product offering is also focused on cervical internal fixation products and its R&D pipeline emphasizes both MAS and motion preservation.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed (particularly with respect to the ongoing clinical trial for NeoDisc(TM)); the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that the Company's financial projections may prove incorrect because of unexpected difficulty in generating sales or achieving anticipated profitability; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at http://www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made. NuVasive further cautions you that the opinions expressed by the physician- participants in the investor reception are entirely their own, have not been developed or scripted by NuVasive, should not be attributed to NuVasive, and may prove to be inaccurate.

Contact: Investors:

Kevin C. O'Boyle Nick Laudico/Zack Kubow

EVP & Chief Financial Officer The Ruth Group

NuVasive, Inc. 646-536-7030/7020

858-909-1800 nlaudico@theruthgroup.com

investorrelations@nuvasive.com zkubow@theruthgroup.com

Media:

Jason Rando

The Ruth Group

646-536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE NuVasive, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Venture Investors early-stage fund grows to $115 million
2. Investor warns of angel-venture funding gap
3. Brazilian bio-industry should impress American investors
4. Investors raise $25 million for biodiesel plant
5. Bio-energy and cleantech grab attention of investors
6. Venture Investors to open Michigan office
7. Early-stage executives hear from investors
8. Commerce qualifies seven for investor tax credits
9. Investor links East Coast funds to Midwest tech
10. Angel investors commit $12.7B in first half of `06
11. Wisconsin investors the lifeblood of New Jersey biotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... HOWELL, N.J. , Dec. 8, 2016 /PRNewswire/ ... aquatic augmentation remediation technologies and selected NewTechBio,s NT-MAX ... , a microbial based beneficial bacteria, in conjunction ... Inc., to correct deficiencies with National Pollutant Discharge ... basin 281-8H has experienced a steady history of ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, Inc. presented ... expansion clinical trial for its lead drug candidate, AC0010, at the World Conference ... was to determine the safety, antitumor activity, and recommended phase II dosage of ...
(Date:12/7/2016)... - OncoQuest Inc. ("OncoQuest"), a biopharmaceutical company focused ... for the treatment of cancer, today announced that ... Program with Cytovance Biologics ( Oklahoma City, ... product. Supported by recent positive interim clinical results ... cancer patients, OncoQuest has engaged Cytovance to establish ...
(Date:12/7/2016)... 8, 2016 The report "Acrylic Processing Aid Market by Polymer Type ... Consumer Goods) - Global Forecast to 2026", published by MarketsandMarkets, the global market ... 1,173.6 Million by 2026, registering an of CAGR of 6.2% between 2016 and ... ... MarketsandMarkets Logo ...
Breaking Biology Technology:
(Date:12/6/2016)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the ... €500.0 million principal amount of its 1.414% senior unsecured notes ... senior unsecured notes due 2026. The closing ... subject to the satisfaction of customary closing conditions.  The notes ... The Company intends to use the net proceeds ...
(Date:12/2/2016)... December 1, 2016 The ... Voice), Future Technology (Iris Recognition System), Vehicle Type ... Global Forecast to 2021", published by MarketsandMarkets, the ... in 2016, and is projected to grow to ... of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/29/2016)... BOSTON , Nov. 29, 2016 BioDirection, ... rapid point-of-care products for the objective detection of concussion ... the company has successfully completed a meeting with the ... company,s Tbit™ blood test Pre-Submission Package. During the meeting ... Tbit™ system as a precursor to commencement of a ...
Breaking Biology News(10 mins):